Braveheart Investment Group PLC (LON:BRH) investee Paraytec's research is being lead by Professor of Cell Biology at University of Sheffield, Carl Smythe for their Covid-19 project.
The clinical sample pipeline for the COVID-19 test developed by Paraytec is now fully operational and Smythe joins Proactive's Katie Pilbeam once again to break down the confusion about the sensitivity and specificity of various types of test.
Smythe also breaks down how the test can be used for large numbers of people, a so-called multiplex or matrix test.